AUTHORS
Katherine Tarlock I, MD, Corinne Summers, MD2, Danielle C. Kirkey, MD3, Rhonda E. Ries, MA4, Maria Pardo5, Andrew J. Menssen, Ph.D., HCLD(ABB)6, Chad A. Hudson, MD, Ph.D7, Anurekha G. Hall, MD, MS8, Colleen Annesley, MD9, Adam Lamble, MD10, Folashade Otegbeye, MBBChir,MPH11, Lara A. Kropp12, Christy Greene13, Armenuhi Avanesyan14, Stefanie Schmuck15, Concetta Quintarelli, PhD16, De Angelis Biagio17, Michael Loken, PhD18, Qian Wu, PhD19, Franco Locatelli, MD PhD20, Soheil Meshinchi, MD, PhD21
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Hematologics, Inc, Seattle, Washington, United States
6 Hematologics, Inc, Seattle, Washington, United States
7 Hematologics, Inc, Seattle, Washington, United States
8 Seattle Children's Hospital, Seattle, Washington, United States
9 Seattle Children's Hospital, Seattle, Washington, United States
10 Seattle Children's Hospital, Seattle, Washington, United States
11 Fred Hutchinson Cancer Center, Seattle, Washington, United States
12 Fred Hutchinson Cancer Center, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Fred Hutchinson Cancer Center, Seattle, Washington, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States
16 Ospedale Pediatric Bambino Gesu, Catholic University of the Sacred Heart, Rome, Italy
17 Ospedale Pediatric Bambino Gesu, Catholic University of the Sacred Heart, Rome, Italy
18 Hematologics, Inc, Seattle, Washington, United States
19 Fred Hutchinson Cancer Center, Seattle, Washington, United States
20 Ospedale Pediatric Bambino Gesu, Catholic University of the Sacred Heart, Rome, Italy
21 Fred Hutchinson Cancer Center, Seattle, Washington, United States
ABSTRACT
A major barrier to cellular therapy in acute myeloid leukemia (AML) has been the lack of AML-restricted antigens, preventing leukemia eradication without toxicity to normal hematopoiesis. The CBFA2T3::GLIS2 (CBF-GLIS) onco-fusion occurs exclusively in infants and very young children, defines RAM AML, and confers highly refractory disease, resulting in uniformly dismal outcomes despite intensive therapies and stem cell transplant. We discovered FOLR1 as a fusion-programmed, direct transcriptional target of the CBF-GLIS fusion and demonstrated its uniform expression in CBF-GLIS AML and its complete absence from normal hematopoiesis, thus establishing FOLR1 as the first AML-restricted therapeutic target. These findings provided the rationale to develop a FOLR1-directed CAR T for this rare disease and test whether selective eradication of AML could be achieved while preserving normal hematopoiesis. We report findings from the initial cohort of our first-in-human phase I trial of the FH-FOLR1 CAR T in infants and young children with relapsed/refractory (R/R) FOLR1+ AML (NCT06609928).
Autologous FH-FOLR1 CAR T cells were generated after CD4/CD8 selection and lentiviral transduction with 2-week expansion/release testing. Key eligibility criteria include R/R AML, FOLR1 expression by flow cytometry, and age ≤6 years. Lymphodepletion (LD) with fludarabine and cyclophosphamide was followed by a single dose of FH-FOLR1 CAR T at DL1 (1x106 cells/kg, N=1) or DL-1 (0.3 x106 cells/kg, N=6).
Seven patients have enrolled with a median age of 2.9 years (range 1.5-4.2). All patients had marrow disease pre-LD (median biopsy blasts 35%; median flow 1%), demonstrating the extraordinary adhesion properties of the disease. Three patients also had active non-CNS extramedullary disease (EMD). Manufacture and infusion were successful in all subjects. Patient #1 treated at DL1 experienced Gr 2 cytokine release syndrome (CRS) and immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). The patient subsequently developed multidrug resistance (MDR) sepsis and experienced DLTs of elevated transaminases, hyperbilirubinemia and prolonged cytopenias. To mitigate potential inflammatory toxicity and infection risk in heavily pre-treated patients, enrollment continued at DL-1. Among the 6 patients treated at DL-1, there was a single DLT of transient elevated transaminases. There were 3 cases of IEC-HS (Gr 1, N=1; Gr 2, N=2) which generally manifested as elevated ferritin and transaminases; no CRS, immune effector cell associated neurotoxicity (ICANS) or significant infections were reported. Importantly, no CAR T-induced hematopoietic toxicity occurred, and all patients had count recovery by D36.
Peak CAR T expansion occurred at median of 14 days (10-16) post infusion with a median peripheral blood CAR T level of 11% (1.3-87%) of circulating lymphocytes. Four patients had robust CAR T expansion (>10%, DL1, N=1; DL-1, N=3) by D14, and the remaining 3 patients had low (1.5%-10%, N=2) or no (<1.5%, N=1) expansion. All 4/4 (100%) patients with robust expansion achieved D28 MRD negative marrow remissions. In contrast, the 3/3 (0%) patients with poor expansion had no marrow response with stable disease at D28. CAR T expansion and clinical response were highly concordant.
Among the 4 responding patients, 2 remain in MRD negative remission after HCT. One had prolonged multidrug-resistant bacteremia and associated cholangitis and cytopenias that precluded HCT and subsequently relapsed with FOLR1-negative leukemia, representing clinical evidence of antigen escape following selective immune pressure. The fourth responsive patient had persistent EMD and relapsed within 2 months with FOLR1+ marrow and EMD disease.
We provide the first prospective clinical evidence that selective targeting of an AML-restricted antigen can induce deep remissions while preserving normal hematopoiesis, addressing a fundamental barrier to AML cellular therapy and validating selective leukemia-restricted antigen targeting as a clinically achievable strategy. The complete concordance between CAR T expansion and MRD-negative remission establishes in vivo expansion as the principal correlate of therapeutic efficacy. Together, these findings establish a new paradigm for AML therapeutic antigen selection and support broader development of fusion-directed cellular therapies. Enrollment is ongoing to define the recommended phase II dose.
DISCLOSURES
Katherine Tarlock I, MD: Seattle Children's Hospital - Current Employment